Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Captor Therapeutics's Days Payable or its related term are showing as below:
WAR:CTX'
s Days Payable Range Over the Past 10 Years
Min: 319.36 Med: 714.55 Max: 2858.74
Current: 2858.74
During the past 9 years, Captor Therapeutics's highest Days Payable was 2858.74. The lowest was 319.36. And the median was 714.55.
WAR:CTX's Days Payable is ranked better than 91.73% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs WAR:CTX: 2858.74
Captor Therapeutics's Days Payable
declined
from Mar. 2025 (377.44) to Mar. 2026 (0.00).
It may suggest that Captor Therapeuticsaccelerated paying its suppliers.
Captor Therapeutics Days Payable Related Terms
Captor Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Captor Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CTX vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Captor Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Captor Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Captor Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Captor Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Captor Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Captor Therapeutics (WAR:CTX) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Captor Therapeutics and its competitors. Over the past decade, Captor Therapeutics' Days Payable has ranged from 319.36 to 2,858.74. According to the industry distribution chart, Captor Therapeutics ranks #58 out of 701 companies in the Biotechnology industry, placing it in the top 8.3%.
Is Captor Therapeutics' Days Payable too high?
Captor Therapeutics' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 319.36 to a high of 2,858.74. Based on the distribution chart, Captor Therapeutics ranks #58 out of 701 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Captor Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Captor Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Captor Therapeutics ranks #58 out of 701 companies for Days Payable. This places Captor Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Historically, Captor Therapeutics' own Days Payable has ranged from 319.36 to 2,858.74 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Captor Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Captor Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Captor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Captor Therapeutics (WAR:CTX) is currently considered Significantly Overvalued. The stock's GF Value™ is zł10.13, compared to a current price of zł73.50 — trading 625.6% above its estimated fair value. The current Days Payable is 0.00. Captor Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Captor Therapeutics (WAR:CTX), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued.
The current stock price of zł73.50 is trading 625.6% above its estimated GF Value™ of zł10.13.
GuruFocus considers Captor Therapeutics to be Significantly Overvalued.
Key valuation signals for WAR:CTX:
Days Payable: 0.00
GF Value™: zł10.13 vs. price of zł73.50 (625.6% above fair value)
No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
38GF Score
Get the complete analysis for WAR:CTX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CTX has been successfully added to your 
